Cannabis info and related links and post from around the web
Enter the DIY cannabis drying chamber, a brilliant build originally shared by Reddit user TheBeardedWizrd. This setup uses a thermoelectric wine cooler to create the perfect drying environment, consistently producing flavorful, properly cured cannabis in about 10 days. Better yet, it costs a fraction of commercial drying units and can be built in an afternoon with basic tools.
Bob Marley was born 78 years ago on Feb. 6, 1945. We remember the Tuff Gong’s great spirit, incredible reggae music and devotion to ganja with this medley of “War” and “No More Trouble.”
Source link
Marijuana, or its derivative THC, continues to be a treacherous quagmire for security clearance holders and adjudicators alike. The latest complication occurred on December 18, 2025, when President Donald Trump signed a new executive order regarding the reclassification of marijuana from a Schedule I controlled substance to a Schedule III controlled substance: “Increasing Medical Marijuana […]
Source link
The prohibitionist group Smart Approaches to Marijuana (SAM) is facing criticism over its decision to deny multiple drug policy reform experts entry to a summit it is hosting in Washington, D.C. this week where the organization will lay out its 2026 priorities and agenda.
Despite billing the 2026 SAM Good Drug Policy Summit as an opportunity for researchers and non-profits to learn how to “educate their communities and employees on all issues surrounding drugs and drug policy,” the pro-reform group Students for Sensible Drug Policy (SSDP) says SAM rejected their attendance and refunded paid tickets for the event.
“We will bring together powerful voices in drug policy from across the field, such as prevention, treatment, recovery, and law enforcement experts to amplify our collective work and scale up drug policy solutions by educating decision-makers and the public about ways to harness science to prevent drug use, treat addiction, and forge pathways to recovery,” SAM, which also partnered with Community Anti-Drug Coalitions of America (CADCA) and the Foundation for Drug Policy Solutions for the conference, said in a description of the event.
Of course, SAM and SSDP hold diametrically opposed viewpoints on the best path to address drug policy issues—with the
The post Scientists And Advocates Slam Anti-Marijuana Group For Blocking Their Participation In D.C. Drug Policy Conference appeared first on GrowCola.com.
Cannabis rescheduling, finally brought back to life by President Donald Trump in December, could help revolutionise clinical cannabis research.
The lack of rigorous, scientific research into the complex effects of cannabis on the body has represented the most significant barrier to its wider acceptance as a treatment in the global medical community, and in turn, further integration into mainstream culture.
This is almost entirely the result of prohibition and the barriers it erected for researchers looking into the plant. While rescheduling could help break down these barriers, the incoming ban on ‘intoxicating hemp’ compounds is set to establish plenty more.
On November 12, 2025, President Trump signed legislation ending the longest government shutdown in US history. Buried within the 144-page funding bill was a provision that will, in less than a year, fundamentally reshape, or potentially destroy, America’s $28 billion hemp industry. The new law redefines hemp to ban most intoxicating cannabinoid products, from delta-8 THC to HHC to THCV. It takes effect on November 13, 2026.
Now, with eleven months on the clock, a new partnership is attempting to provide rigorous, data-driven scientific evidence about what these cannabinoids actually do before they endure the same decades-long battle for clarity as cannabis.
Yet, with the clock ticking, traditional clinical trials would only just be getting started before the ban is enacted.
Standard Seed Corporation offers an innovative and potentially transformational alternative. The AI-powered botanical research platform has partnered with the American Healthy Alternatives Association (AHAA), a grassroots hemp advocacy organisation, alongside a growing number of other interested companies, to aggregate consumer data, map molecular interactions, and translate complex cannabinoid science into accessible, digestible information.
The goal isn’t advocacy, according to the partners. It’s filling a dangerous knowledge gap before regulators make irreversible decisions based on incomplete information.
When the 2018 Farm Bill legalised hemp, it inadvertently created a loophole that allowed semi-synthetic cannabinoids like delta-8 THC and HHC to proliferate across the United States much faster than research was able to keep up with.
Europe’s recent experience with delta-8 THC illustrates the problem. When European regulators issued their first official position paper on the compound in 2025, their conclusion was stark: we don’t know enough to regulate this any differently than delta-9 THC.
The November funding bill doesn’t just target specific compounds, it creates a sweeping ‘similar effects’ standard that gives federal agencies broad authority to classify any cannabinoid that produces THC-like effects as an illegal substance.
For Kevin Kimmell, B2B Marketing Strategist at Arvida Labs, which manufactures cannabinoid products for brands including Mellow Fellow, the frustration is palpable: “We want to say, hey, this is not just frankenoids or these random cannabinoids.
“We have spent the best part of the last decade developing and perfecting a method of converting cannabinoids safely with no residual solvents or byproducts with our specialist scientific team. Now we’re working on more science to figure out why people like these compounds and what exactly they’re doing.”
The collaboration’s approach centres on pairing two types of evidence that have rarely been combined in cannabis research: computational predictions of how cannabinoids interact with human proteins, and systematic analysis of how thousands of real consumers actually use these products.
Standard Seed’s platform uses artificial intelligence to predict molecular interactions, the same computational drug design techniques used by pharmaceutical companies. The technology can map how a cannabinoid like THCV binds to specific receptor families, which biological pathways it affects, and what outcomes those interactions might produce. Crucially, it can generate these predictions in roughly 30 minutes for new compounds. For example, THCV hits the PPAR Gamma Receptors and Thyroid Hormones which give rise to metabolic effects.
But computational predictions alone aren’t enough. The collaboration pairs Standard Seed’s molecular modelling with real-world consumer data from thousands of product reviews, usage patterns, and reported effects.
Take CBN, widely marketed for sleep. Consumer data shows typical doses around 10 milligrams, with onset times of 30-40 minutes, patterns that align with Standard Seed’s predictions about which neural pathways and receptors the compound affects. Or HHC, where certain isomers appear to interact with the same photosensitivity receptors that regulate circadian rhythm, potentially explaining why consumers report sleep-promoting effects.
“The most enlightening combination is when I have a real-world story, and then we relate that with data,” Coombs notes. “We’re doing real-life clinical trials here, in a way.”
The partnership has developed visual tools to make this complex science accessible. A “Sankey diagram” traces the path from individual cannabinoids through receptor families to biological outcomes to consumer use cases, distilling thousands of molecular predictions into a single reference.
Interactive Demo: Explore the molecular pathways on the Standard Seed platform.
In a significant departure from the catch-all marketing that ultimately drew the ire of politicians, the partners are developing comprehensive warning labels and safety guidelines for minor cannabinoids, and ensuring populations who shouldn’t use them are identified and informed.
The collaboration also plans to publish dosing tables with recommended ranges and upper limits for key cannabinoids.
“Being transparent about risks is super important,” Coombs notes. “We need to avoid just putting across the benefits and not being realistic about the risks.”
By acknowledging genuine risks and appropriate use limitations, the collaboration aims to establish much-needed legitimacy and trust with national regulators.
Within 90 days of enactment (by February 10, 2026), the FDA must publish lists identifying which cannabinoids occur naturally in cannabis, which belong to the THC family, and which have THC-like effects.
That February FDA guidance will be crucial. Regulators will need to make scientific determinations about cannabinoid classifications, the precise kind of evidence this collaboration aims to support.
JD McCormick, founder of AHAA, explained: “This collaboration is about giving lawmakers the tools they need to make evidence-based decisions and showing them how those decisions translate into real products that support jobs and families.”
AHAA has mobilised thousands of grassroots supporters and coordinated more than $750,000 in brand donations in 2025 alone to fight hemp restrictions.
The post Racing the Clock: Hemp Industry Scrambles to Build Scientific Case Before 2026 Ban appeared first on Business of Cannabis.
IRVINE, Calif. — WM Technology Inc. appointed Harry DeMott and Brent Cox to the company’s board of directors, effective February 1.
DeMott is an investor, operator, and board member with experience spanning cannabis and technology. He is a general partner at Raptor Ventures, which he co-founded, and is part of the founding group at Outsider Labs, an AI startup. He previously founded and served as CEO of Proper, a data company focused on the cannabis industry, and has served on public-company boards including Workhorse Group Inc., where he chaired the compensation committee, and Achari Ventures Holdings Corp., where he chaired the audit committee. He holds an A.B. in economics from Princeton University and an M.B.A. from New York University’s Stern School of Business.
Cox is a seasoned investment professional and board advisor with experience across growth and regulated businesses, including cannabis. He is founder and managing principal of Subtext Holdings, a private investment firm with an emphasis on high-growth emerging markets and regulated industries, and co-founder and managing partner at The Inception Companies, a private investment firm. He currently serves on the board of Ispire Technology, with prior cannabis board experience including MedMen, Sunday Goods, Sherbinskis, Wellgreens, and Pacific Dutch Group. Cox began his career in the Leveraged Finance Group at Jefferies & Co. and holds a B.S. in accounting from the University of Southern California.
Wisconsin senators have approved a bill to legalize medical marijuana in the state as other legislators push for broader adult-use legalization.
The Senate Health Committee on Thursday advanced the medical cannabis legislation from Senate President Mary Felzkowski (R) and Sen. Patrick Testin (R) in a 4-1 vote. This comes months after the panel held an initial hearing on the GOP-led proposal, which was introduced last October.
Wisconsin’s GOP Assembly speaker said last year that he hoped lawmakers in the state could “find a consensus” on legislation to legalize medical marijuana. But he added that the cannabis bill filed by his Republican leadership counterpart in the Senate was “unlikely” to pass his chamber because it is “way too broad and way too wide-ranging.”
Assembly Speaker Robin Vos (R) also said last month that President Donald Trump made the “wrong” choice to order the rescheduling of marijuana—which he called a “dangerous drug”—but he said the upside is that research barriers may be lifted in a way that demonstrates medical cannabis can be effectively used in a limited way as an alternative to prescription medications.
However, the speaker said he thinks “we are not there” in terms of having enough votes to advance
The post Wisconsin Senators Approve GOP-Led Medical Marijuana Bill As Democrats Push Broader Recreational Legalization appeared first on GrowCola.com.
The Mississippi House of Representatives has approved a bill to allow terminally ill patients to access medical marijuana in hospitals, nursing facilities and hospice centers.
About a week after advancing out of the House Public Health and Human Services Committee, the full chamber passed the legislation from Rep. Kevin Felsher (R) in a 117-1 vote on Wednesday.
Known as “Ryan’s Law,” an acknowledgement of a young cannabis patient who passed and whose father has since become an advocate for access in hospital settings, the bill is meant to “support the ability of terminally ill qualifying patients to safely use medical cannabis within specified health care facilities.”
“Ryan’s Law is rooted in one simple principle: at the end of life, compassion and medical judgment should come before bureaucracy,” Felsher said on the floor before the vote. “This legislation will allow terminally ill qualifying patients to safely use medical cannabis within a specific healthcare facility, including hospitals, skilled nursing facilities and hospice facilities.”
The legislation would require hospitals, skilled nursing facilities and hospice centers to “allow terminally ill qualifying patients in the facility to use medical cannabis” in forms other than smoking or vaping.
There’s also another carve-out in the
The post Mississippi House Approves Bill To To Allow Medical Marijuana Use In Hospitals For Terminally Ill Patients appeared first on GrowCola.com.
